miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status

Lu,Zhenduo; Ye,Yuping; Jiao,Dechuang; Qiao,Jianhua; Cui,Shude; Liu,Zhenzhen

doi:10.3892/ol.2012.841

miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status

Authors:
- Zhenduo Lu
- Yuping Ye
- Dechuang Jiao
- Jianhua Qiao
- Shude Cui
- Zhenzhen Liu
View Affiliations

Affiliations: Breast Cancer Center, Henan Cancer Hospital and Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 45008, P.R. China
Published online on: August 3, 2012 https://doi.org/10.3892/ol.2012.841
Pages: 1027-1032

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to determine the tissue and plasma levels of microRNA (miR)-155 and miR-31 in 67 patients with invasive intraductal breast cancer and their correlation with the clinicopathological characteristics. Using a quantitative real-time-PCR (qRT-PCR) assay, it was demonstrated that the plasma levels of miR-155 and miR-31 in patients were 6- and 5-fold higher than those in healthy individuals, respectively (P<0.05). In cancerous tissues, miR-155 expression levels were 5-fold higher compared with those in non-cancerous tissues (P<0.05), whereas no difference was observed with miR-31 expression (P>0.05). The expression levels of miR-155, but not miR-31, were inversely correlated with estrogen receptor (ER) and progesterone receptor (PR) expression (ER, r=-0.353, P=0.003; PR, r=-0.357, P=0.003). The tissue and plasma levels of miR-155 and miR-31 were not correlated with epidermal growth factor receptor-2 (HER-2) expression levels. Furthermore, high levels of plasma miR-155 and miR-31 were identified in the tumors of TNM stage II, lymph node metastasis 0-3 and tumor sizes of 2-5 cm in patients who were aged over 52 years. miR-155 was mainly expressed in patients with a pathology score of 3 for ER or PR expression; miR-31 expression was higher in patients with a pathology score of 2. These results suggest that miR-155 and miR-31 are differentially expressed in breast cancer patients. Their correlation with the clinicopathological characteristics may aid the diagnosis and treatment of invasive intraductal breast cancer.

View Figures

View References

1.	A JemalF BrayMM CenterJ FerlayE WardD FormanGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.20107
2.	MV IorioM FerracinCG LiuMicroRNA gene expression deregulation in human breast cancerCancer Res6570657070200510.1158/0008-5472.CAN-05-178316103053
3.	H MouridsenA Giobbie-HurderA GoldhirschBIG 1-98 Collaborative Group: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med361766776200910.1056/NEJMoa081081819692688
4.	JF ForbesJ CuzickA BuzdarA HowellJS TobiasM BaumArimidex, Tamoxifen, Alone or in Combination GroupEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol94553200810.1016/S1470-2045(07)70385-618083636
5.	Early Breast Cancer Trialist’s Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet36516871717200515894097
6.	GA CalinCM CroceMicroRNA signatures in human cancersNat Rev Cancer6857866200610.1038/nrc199717060945
7.	GA CalinCM CroceMicroRNA-cancer connection: the beginning of a new taleCancer Res6673907394200610.1158/0008-5472.CAN-06-080016885332
8.	K JeyaseelanWB HerathA ArmugamMicroRNAs as therapeutic targets in human diseasesExpert Opin Ther Targets1111191129200710.1517/14728222.11.8.111917665982
9.	CE Stahlhut EspinosaFJ SlackThe role of microRNAs in cancerYale J Biol Med791311402006
10.	A Esquela-KerscherFJ SlackOncomirs - microRNAs with a role in cancerNat Rev Cancer6259269200610.1038/nrc1840
11.	SF TavazoieC AlarcónT OskarssonEndogenous human microRNAs that suppress breast cancer metastasisNature451147152200810.1038/nature0648718185580
12.	W ZhuW QinU AtasoyER SauterCirculating microRNAs in breast cancer and healthy subjectsBMC Res Notes289200910.1186/1756-0500-2-8919454029
13.	I FaraoniFR AntonettiJ CardoneE BonmassarmiR-155 gene: a typical multifunctional microRNABiochim Biophys Acta1792497505200910.1016/j.bbadis.2009.02.01319268705
14.	RM O’ConnellAA ChaudhuriDS RaoD BaltimoreInositol phosphatase SHIP1 is a primary target of miR-155Proc Natl Acad Sci USA10671137118200919359473
15.	S JiangHW ZhangMH LuMicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 geneCancer Res7031193127201010.1158/0008-5472.CAN-09-425020354188
16.	E TiliJJ MichailleD WernickeMutator activity induced by microRNA-155 (miR-155) links inflammation and cancerProc Natl Acad Sci USA10849084913201110.1073/pnas.110179510821383199
17.	S ValastyanF ReinhardtN BenaichA pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasisCell13710321046200910.1016/j.cell.2009.03.04719524507
18.	S ValastyanA ChangN BenaichF ReinhardtRA WeinbergActivation of miR-31 function in already-established metastases elicits metastatic regressionGenes Dev25646659201110.1101/gad.200421121406558
19.	S ValastyanRA WeinbergmiR-31: a crucial overseer of tumor metastasis and other emerging rolesCell Cycle921242129201010.4161/cc.9.11.1184320505365
20.	CJ LiuSY KaoHF TuMM TsaiKW ChangSC LinIncrease of microRNA miR-31 level in plasma could be a potential marker of oral cancerOral Dis16360364201010.1111/j.1601-0825.2009.01646.x20233326
21.	RA SiniB TrinkA NissanThe role of microRNA in tumorigenesis: key players or innocent bystandersJ Surg Oncol99135136200910.1002/jso.2121319072979
22.	NB TsuiEK NgYM LoStability of endogenous and added RNA in blood specimens, serum, and plasmaClin Chem4816471653200212324479
23.	PS MitchellRK ParkinEM KrohCirculating microRNAs as stable blood-based markers for cancer detectionProc Natl Acad Sci USA1051051310518200810.1073/pnas.080454910518663219
24.	H ZhaoJ ShenL MedicoD WangCB AmbrosoneS LiuA pilot study of circulating miRNAs as potential biomarkers of early stage breast cancerPLoS One5e13735201010.1371/journal.pone.001373521060830
25.	J ZhuXQ HuGL GuoExpression and its clinical significance of miR-155 in human primary breast cancerZhonghua Wai Ke Za Zhi482052082010(In Chinese)
26.	N HabbeJB KoorstraJT MendellMicroRNA miR-155 is a biomarker of early pancreatic neoplasiaCancer Biol Ther8340346200910.4161/cbt.8.4.733819106647
27.	T DonnemK EkloT BergPrognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridizationJ Transl Med96201110.1186/1479-5876-9-621219656
28.	S VoliniaGA CalinCG LiuA microRNA expression signature of human solid tumors defines cancer gene targetsProc Natl Acad Sci USA10322572261200610.1073/pnas.051056510316461460
29.	E TiliCM CroceJJ MichaillemiR-155: on the crosstalk between inflammation and cancerInt Rev Immunol28264284200910.1080/0883018090309379619811312
30.	HM HeneghanN MillerAJ LoweryKJ SweeneyJ NewellMJ KerinCirculating microRNAs as novel minimally invasive biomarkers for breast cancerAnn Surg251499505201010.1097/SLA.0b013e3181cc939f20134314
31.	CH StueltenDS SalomonmiR-31 in cancer: location mattersCell Cycle946084609201010.4161/cc.9.23.1392821260945